MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data

Shares of Moderna (MRNA) are on track for their best year on record as investors await detailed melanoma trial results, while an analyst said that China leads the U.S. in AI-driven drug development lack credible evidence.Over the past year, the U.S.-focused SPDR S&P Biotech ETF (XBI) gained 62%, wh…